Leaflet ATOVAQUON/PROGUANILHYDROCHLORID GLENMARK 250mg / 100mg film-coated tablets

Product code:
W68843001
Quantity:
12
Indicated for:
malaria
Route of administration:
oral
Substance:
atovaquone + proguanil (antimalarials)
ATC
P01BB51 — Antiparasitic products, insecticides and repellents | Antimalarials | Biguanides
Atovaquone+proguanil is a combination medication used for the prevention and treatment of malaria, an infectious disease caused by Plasmodium parasites. Atovaquone works by inhibiting electron transport in the parasite's mitochondria, while proguanil is a dihydrofolate reductase inhibitor, interfering with the parasite's DNA synthesis.

This combination is administered orally, usually once daily, and is indicated for both malaria prophylaxis in travelers and the treatment of acute uncomplicated malaria. It is effective against multiple Plasmodium species, including P. falciparum, which is resistant to other antimalarial drugs.

Common side effects include nausea, vomiting, abdominal pain, and headache. In rare cases, severe adverse reactions such as allergic reactions or liver function impairment may occur. It is important for patients to adhere to the recommended dosing schedule to prevent the development of parasite resistance.

Atovaquone+proguanil is a safe and effective option for the prevention and treatment of malaria, contributing to the global effort to reduce the burden of this infectious disease.

General data about ATOVAQUON/PROGUANILHYDROCHLORID GLENMARK 250mg / 100mg

Substance:
atovaquone + proguanil
Date of latest medicines list:
01-07-2023
Product code:
W68843001
Concentration:
250mg / 100mg
Pharmaceutical form:
film-coated tablets
Quantity:
12
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
GLENMARK PHARMACEUTICALS S.R.O - REPUBLICA CEHA
Holder:
CN UNIFARM S.A. - ROMANIA
Number:
714/2022/01